The Biotech Industry is driven by catalysts. It is crucial for investors to monitor recent events and analyze the impact they have had on share prices. The Biotech Industry has slumped as recent news has caused some dramatic swings, with the losses more than offsetting the gains. The iShares NASDAQ Biotechnology Index ETF (IBB) and the SPDR S&P Biotech ETF (XBI) have dropped roughly 5.7 percent and 3.2 percent, respectively, in the past week.
Albany Molecular Research, Inc. (NASDAQ: AMRI) shares traded in the range of $10.94 to $11.44 Thursday before settling to close at $10.95, a decrease of 4.20 percent. The stock appears to be facing some resistance at the $11.05 and $11.35 levels with some support at $10.83. The company earlier this week announced that Bristol-Myers Squibb was discontinuing the development of BMS-820836, an experimental depression treatment.
More information on Albany Molecular Research and access to the free equity report can be found at:
Osiris Therapeutics, Inc. (NASDAQ: OSIR) shares traded in the range of $19.41 to $21.73 Thursday before settling to close at $19.76, a decrease of 11.99 percent. The stock appears to be facing some resistance at $21.90. The company earlier this week announced Grafix demonstrated "overwhelming efficacy" in a landmark stem cell study for the treatment of diabetic foot ulcers.
More information on Osiris Therapeutics and access to the free equity report can be found at:
Rexahn Pharmaceuticals, Inc. (NYSEMKT: RNN) shares traded in the range of $0.43 to $0.46 Thursday before settling to close at $0.45, a decrease of 2.17 percent. The stock appears to be facing some resistance at the $0.51 and $0.57 levels with some support at $0.41. The company has recently initiated dosing in a Phase 1 trial of Supinoxin, a candidate for treating solid cancer tumors.
More information on Rexahn Pharmaceuticals and access to the free equity report can be found at:
Sequenom, Inc. (NASDAQ: SQNM) shares traded in the range of $2.92 to $3.03 Thursday before settling to close at $2.98, an increase of 0.68 percent. The stock appears to be facing some resistance at the $3.02 and $3.13 levels with some support at $2.95. The company reported net loss for the second quarter of 2013 grew to $31.0 million from a loss of $29.6 million a year ago.
More information on Sequenom and access to the free equity report can be found at:
Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.
Activate your always free membership by signing up at www.WallStreetFundamentals.com today.
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.
Wall Street Fundamentals